Trials / Completed
CompletedNCT03920852
A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label maximum use trial to evaluate ruxolitinib safety and blood levels after its topical application twice daily to affected areas (≥ 25% BSA) in adolescent and adult participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib cream | Ruxolitinib 1.5% cream applied twice daily. |
Timeline
- Start date
- 2019-05-30
- Primary completion
- 2019-12-26
- Completion
- 2019-12-26
- First posted
- 2019-04-19
- Last updated
- 2020-02-17
Locations
10 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03920852. Inclusion in this directory is not an endorsement.